摘要:
This disclosure is related to a perforator tool and a method of using the perforator tool to perforate a formation. The perforator tool can include a first and second sleeve and optionally a third sleeve. The perforator tool can also include at least one perforation opening and at least one circulation port. The sleeves are slidably disposed within the perforator tool and can be displaced to permit perforation of the formation, block the perforation openings and open circulation ports.
摘要:
This disclosure is related to a perforator tool and a method of using the perforator tool to perforate a formation. The perforator tool can include a first and second sleeve and optionally a third sleeve. The perforator tool can also include at least one perforation opening and at least one circulation port. The sleeves are slidably disposed within the perforator tool and can be displaced to permit perforation of the formation, block the perforation openings and open circulation ports.
摘要:
The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
摘要:
The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
摘要:
The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
摘要:
The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.